natgillin/translations-raw huggingface dataset:
Co-administration of Lopinavir/Ritonavir Mylan with rifampicin is not recommended as the decrease in lopinavir concentrations may in turn significantly decrease the lopinavir therapeutic effect. 
Istodobna primjena lijeka Lopinavir/Ritonavir Mylan s rifampicinom se ne preporučuje jer smanjenje koncentracije lopinavira može značajno smanjiti terapijski učinak lopinavira.
≥ 0.8 to < 1.2 
 0,8 do < 1,2
Felodipine, Nifedipine, Nicardipine: Concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir. 
Felodipin, nifedipin, nikardipin: Koncentracije mogu biti povećane zbog inhibicijskog učinka lopinavira/ritonavira na CYP3A.
It is important to note that cases of pancreatitis have been reported in patients receiving lopinavir/ritonavir, including those who developed hypertriglyceridaemia. 
Važno je napomenuti da je u bolesnika koji su uzimali lopinavira/ritonavira bilo i prijava pankreatitisa, uključivši i one u kojih je nastupila hipertrigliceridemija.
Patients should be informed that nausea has been reported during treatment with lopinavir/ritonavir (see section 4.8). 
Bolesnici moraju biti informirani da je zabilježena mučnina tijekom liječenja lopinavirom/ritonavirom (vidjeti dio 4.8).
Rifampicin in combination with lopinavir/ritonavir causes large decreases in lopinavir concentrations which may in turn significantly decrease the lopinavir therapeutic effect. 
Rifampicin u kombinaciji s lopinavirom/ritonavirom može značajno sniziti koncentracije lopinavira i tako znatno smanjiti njegov terapijski učinak.
This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products. 
To može dovesti do sniženih koncentracija u plazmi i mogućeg smanjenja učinkovitosti lijekova koji se uzimaju istodobno s lopinavirom/ritonavirom.
Increased plasma concentrations of ranolazine which may increase the potential for serious and/or life-threatening reactions (see section 4.5). 
Povišena koncentracija ranolazina u plazmi, što može povećati mogućnost nastupa ozbiljnih i/ili po život opasnih reakcija (vidjeti dio 4.5).
Name and address of the manufacturers responsible for batch release 
Naziv i adresa proizvođača odgovornog(ih) za puštanje serije lijeka u promet
Post-marketing cases have been reported indicating a potential interaction between ritonavir containing products and levothyroxine. 
Nakon stavljanja lijeka u promet zabilježeni su slučajevi koji upućuju na moguću interakciju između lijekova koji sadrže ritonavir i levotiroksina.
Lopinavir/ritonavir is contraindicated in patients with severe liver impairment (see section 4.3). 
Lopinavir/ritonavir je kontraindiciran u bolesnika s vrlo teškim poremećajem funkcije jetre (vidjeti dio 4.3).
Multiple dosing of 800/200 mg lopinavir/ritonavir once daily for 2 weeks without meal restriction (n=16) produced a mean ± SD lopinavir peak plasma concentration (Cmax) of 14.8 ± 3.5 μg/ml, occurring approximately 6 hours after administration. 
Višekratne doze lopinavira/ritonavira 800/200 mg jednom dnevno kroz 2 tjedna bez ograničavanja jela (n = 16) proizvele su srednje vrijednosti ± SD maksimalne koncentracije lopinavira u plazmi (Cmax) od 14,8 ± 3,5 μg/ml, koje se postižu otprilike 6 sati nakon primjene.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po doznoj jedinici, tj zanemarive količine natrija.
- The active substances are lopinavir and ritonavir - The other ingredients are sorbitan laurate, colloidal anhydrous silica, copovidone, sodium stearyl fumarate, hypromellose, titanium dioxide (E171), macrogol, hydroxypropylcellulose, talc, polysorbate 
- Drugi sastojci su sorbitanlaurat, koloidni bezvodni silicijev dioksid, kopovidon, natrijev stearilfumarate, hipromeloza, titanijev dioksid (E171), makrogol, hidroksipropilceluloza, talk,
Paediatric dosing guidelines with concomitant efavirenz or nevirapine 
Smjernice za pedijatrijsko doziranje s istodobnom primjenom efavirenza ili neviparina
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway e.g. budesonide and triamcinolone. 
Učinci sistemskih kortikosteroida, uključujući Cushingov sindrom i supresiju adrenalne funkcije, prijavljeni su u bolesnika koji su primali ritonavir i inhalacijski ili intranazalno primjenjen flutikazonpropionat; ti su učinci mogući i pri primjeni drugih kortikosteroida koji se metaboliziraju putem P450 3A, npr. pri primjeni budezonida i triamcinolona.
If you or your child take more Lopinavir/Ritonavir Mylan than you should 
Ako Vi ili Vaše dijete uzmete više lijeka Lopinavir/Ritonavir Mylan nego što ste trebali
MARKETING AUTHORISATION NUMBER EU/1/15/1067/001 - 60 Film-coated tablets EU/1/15/1067/002 - 60x1 Film-coated tablets 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/15/1067/001 - 60 filmom obloženih tableta EU/1/15/1067/002 - 60 x 1 filmom obloženih tableta
The mean steady-state trough concentration prior to the morning dose was 8.1 ± 5.7 μg/ml. 
Srednja vrijednost najniže koncentracije u stanju dinamičke ravnoteže, prije jutarnje doze, iznosila je 8,1 ± 5,7 μg/ml.
Thyroid stimulating hormone (TSH) should be monitored in patients treated with levothyroxine at least the first month after starting and/or ending lopinavir/ritonavir treatment. 
U bolesnika liječenih levotiroksinom potrebno je pratiti tireostimulirajući hormon (TSH) barem prvi mjesec nakon početka i/ili kraja liječenja lopinavirom/ritonavirom.
The dose of maraviroc should be decreased to 150 mg twice daily during co-administration with Lopinavir/Ritonavir Mylan 400/100 mg twice daily. 
Dozu maraviroka treba smanjiti na 150 mg dvaput na dan prilikom istodobne primjene s lijekom Lopinavir/Ritonavir Mylan 400/100 mg dvaput na dan.
Potential for serious and/or lifethreatening reactions in patients with renal and/or hepatic impairment (see sections 4.4 and 4.5). 
Moguće ozbiljne i/ili po život opasne reakcije u bolesnika s oštećenjem funkcije bubrega i/ili jetre (vidjeti dijelove 4.4 i 4.5).
Lopinavir/Ritonavir Mylan must not be co-administered with oral midazolam (see section 4.3), whereas caution should be used with coadministration of Lopinavir/Ritonavir Mylan and parenteral midazolam. 
Lopinavir/ritonavir Mylan se ne smije davati istodobno s oralnim midazolamom (vidjeti dio 4.3), a pri istodobnoj primjeni lijeka Lopinavir/Ritonavir Mylan s parenteralnim midazolamom nužan je oprez.
What you need to know before you or your child takes Lopinavir/Ritonavir Mylan 
Što morate znati prije nego vi ili vaše dijete počnete uzimati Lopinavir/Ritonavir Mylan
Unchanged lopinavir accounted for approximately 2.2% and 19.8% of the administered dose in urine and faeces, respectively. 
U nepromijenjenu se obliku u urin izlučilo oko 2,2%, a u feces oko 19,8% lopinavira.
Concomitant administration of Lopinavir/Ritonavir Mylan and quetiapine is contraindicated as it may increase quetiapine-related toxicity. 
Istodobna primjena lijeka Lopinavir/Ritonavir Mylan i kvetiapina je kontraindicirana jer može povećati toksičnost povezanu s kvetiapinom.
AUC: ↑ 11.86-fold Cmax: ↑ 6.31-fold C24: ↑ 20.70-fold 
AUC: ↑ 11,86 puta Cmax: ↑ 6,31 put C24: ↑ 20,70 puta
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. 
Nakon početka uzimanja lijeka za liječenje Vaše infekcije HIV-om, uz oportunističke infekcije dodatno se mogu pojaviti autoimuni poremećaji (stanja koja se događaju kada imunološki sustav napadne zdravo tkivo).
Increased plasma concentrations of paritaprevir; thereby, increasing the risk of alanine transaminase (ALT) elevations (see section 4.5). 
Povišena koncentracija paritaprevira u plazmi; time je povišen rizik od povećanja razine alanin transaminaze (ALT) (vidjeti dio 4.5).
Lopinavir/ritonavir has not specifically been tested for its possible effects on the ability to drive a car or operate machines. 
Nije posebno proučavan učinak lopinavira/ritonavira na sposobnost upravljanja vozilima i strojevima.
However, if the benefit outweighs the risk, co-administration of bedaquiline with lopinavir/ritonavir must be done with caution. 
Međutim, ukoliko korist nadmašuje rizik, prilikom istodobne primjene bedakilina s lopinavirom/ritonavirom potreban je oprez.
Co-administration of lopinavir/ritonavir with these medicinal products is expected to substantially increase their concentrations and may result in associated adverse events such as hypotension, syncope, visual changes and prolonged erection (see section 4.5). 
Istodobna primjena lopinavira/ritonavira s ovim lijekovima može znatno povećati njihove koncentracije u krvi i rezultirati pratećim štetnim događajima kao što su hipotenzija, sinkopa, promjene vida i produžena erekcija (vidjeti dio 4.5).
Increased plasma concentrations of lovastatin and simvastatin; thereby, increasing the risk of myopathy including rhabdomyolysis (see section 4.5). 
Povišena koncentracija lovastatina i simvastatina u plazmi; time je povišen rizik od miopatije, uključujući rabdomiolozu (vidjeti dio 4.5).
Therefore, Lopinavir/Ritonavir Mylan can be started safely 2 weeks after cessation of St John's wort. 
Stoga primjenu lijeka Lopinavir/Ritonavir Mylan, da bi bila sigurna, treba početi dva tjedna nakon obustave gospine trave.
However, such a dose adjustment might be associated with ALT/AST elevations and with increase in gastrointestinal disorders. 
No takvo prilagođavanje doze može biti povezano s porastom razina ALT/AST i s porastom
Concomitant administration of Lopinavir/Ritonavir Mylan with fusidic acid is contra-indicated in dermatological indications due to the increased risk of adverse events related to fusidic acid, notably rhabdomyolysis (see section 4.3). 
Istodobna primjena lijeka Lopinavir/Ritonavir Mylan s fusidatnom kiselinom je kontraindicirana kod dermatoloških indikacija zbog povećanog rizika od štetnih događaja povezanih s fusidatnom kiselinom, osobito rabdomiolize (vidjeti dio 4.3).
Refer to the ceritinib SmPC for dosage adjustment recommendations. 
Vidjeti Sažetak opisa svojstava lijeka za ceritinib za preporuke za prilagodbu doze.
Rare reports of 2nd or 3rd degree atroventricular block in patients with underlying structural heart disease and pre-existing conduction system abnormalities or in patients receiving drugs known to prolong the PR interval (such as verapamil or atazanavir) have been reported in patients receiving lopinavir/ritonavir. 
U bolesnika koji su uzimali lopinavir/ritonavir zabilježeni su rijetki slučajevi AV bloka drugog i trećeg stupnja u bolesnika s podležećom strukturalnom bolesti srca i prethodno prisutnim poremećajem sustava provođenja impulsa u srcu ili slučajevi bolesnika koji su uzimali lijekove za koje je poznato da izazvaju prolongaciju PR intervala (poput verapamila ili atazanavira).
Increased plasma concentrations of lurasidone which may increase the potential for serious and/or life threatening reactions (see section 4.5) 
Povišena koncentracija lurasidona u plazmi, što može povećati mogućnost nastupa ozbiljnih i/ili po život opasnih reakcija (vidjeti dio 4.5).
Lopinavir/ritonavir medicinal product level decreased Herbal products 
Smanjenje razina lijeka lopinavir/ritonavir Biljni lijekovi
− Do not take lopinavir/ritonavir if you are currently taking avanafil or vardenafil. 
Lijekovi za liječenje erektilne disfunkcije (avanafil, vardenafil, sildenafil, tadalafil) Ne uzimajte lopinavir/ritonavir ako trenutno uzimate avanafil ili vardenafil.
They were randomised in a 1:1 ratio to receive either lopinavir/ritonavir 800/200 mg once daily (n = 300) or lopinavir/ritonavir 400/100 mg twice daily (n = 299). 
Bili su randomizirani u omjeru 1:1 te su primali 800/200 mg lopinavir/ritonavira jednom dnevno (n = 300), odnosno 400/100 mg lopinavir/ritonavira dva puta dnevno (n = 299).
The study did not contain a control arm of patients not receiving lopinavir/ritonavir. 
U ispitivanju nije bilo kontrolne skupine bolesnika bez terapije lopinavirom/ritonavirom.
Particular caution must be used when prescribing sildenafil or tadalafil in patients receiving Lopinavir/Ritonavir Mylan with increased monitoring for adverse events including hypotension, syncope, visual changes and prolonged erection (see section 4.4). 
Pri propisivanju sildenafila ili tadalafila bolesnicima koji primaju Lopinavir/Ritonavir Mylan nužni su poseban oprez i pozornije praćenje štetnih događaja koji uključuju hipotenziju, sinkopu, promjene vida i produženu erekciju (vidjeti dio 4.4).
The two regimens resulted in exposures on Day 3 which were approximately 1.5 and 3-fold higher than those observed with recommended oncedaily or twicedaily LPV/r doses at steady state. 
Ova dva režima uzimanja lopinavira/ritonavira u trećem su danu studije rezultirala izloženošću lijeku koja je 1,5 i 3 puta veća nego ona uočena u bolesnika koji su uzimali preporučenu dozu lopinavira/ritonavira jednom ili dva puta dnevno, u stanju dinamičke ravnoteže.
Once-daily dosing: the pharmacokinetics of once daily lopinavir/ritonavir have been evaluated in HIVinfected subjects naïve to antiretroviral treatment. 
Doziranje jednom dnevno: procijenjivana je farmakokinetika doziranja lopinavira/ritonavira jednom dnevno kod bolesnika zaraženih HIV-om koji nisu prethodno primali antiretrovirusne lijekove.
Furthermore, rare increases in PR interval have been reported during lopinavir/ritonavir therapy (see section 4.4). 
Bilo je, nadalje, i rijetkih prijava produženog PR-intervala pri uzimanju lopinavira/ritonavira (vidjeti dio 4.4).
Multipack: 360 (3 bottles of 120) film-coated tablets 
Višestruko pakiranje: 360 (3 kutije sa 120) filmom obloženih tableta
− If a side effect is preventing you from taking lopinavir/ritonavir as directed tell your doctor right away. 
Ukoliko zbog nuspojave ne možete nastaviti uzimati lopinavir/ritonavir, recite to svom liječniku odmah.
The maximum mean (95% upper confidence bound) differences in QTcF from placebo were 3.6 (6.3) and 13.1(15.8) for 400/100 mg twice daily and supratherapeutic 800/200 mg twice daily LPV/r, respectively. 
Najveće razlike srednjih vrijednosti QTcF-a (Interval pouzdanosti uz 95% vjerojatnost) u odnosu na placebo bile su 3,6 (6,3) u bolesnika koji su uzimali 400/100 mg lopinavira/ritonavira dva puta dnevno i 13,1 (15,8) u bolesnika koji su uzimali supraterapijsku dozu od 800/200 mg lopinavira/ritonavira dva puta dnevno.
Activity of other protease inhibitors against isolates that developed incremental resistance to lopinavir after lopinavir/ritonavir therapy in protease inhibitor experienced patients: The presence of cross resistance to other protease inhibitors was analysed in 18 rebound isolates that had demonstrated evolution of resistance to lopinavir during 3 Phase II and one Phase III studies of lopinavir/ritonavir in protease inhibitor-experienced patients. 
Aktivnost ostalih inhibitora proteaze kod izoliranih sojeva koji su razvili pojačanu otpornost na lopinavir nakon terapije lopinavirom/ritonavirom u bolesnika koji su već uzimali inhibitore proteaze: Prisutnost križne rezistencije na druge inhibitore proteaze je analizirana u 18 izoliranih sojeva u bolesnika s ponovnim porastom broja virusa.
Please refer to the Aptivus Summary of Product Characteristics for additional information on the use of tipranavir, including genotypic predictors of response, in treatment of lopinavir-resistant HIV-1 infection. 
Za detaljnije podatke o primjeni tipranavira, uključujući genotipske prediktore odgovora, u terapiji HIV-1 infekcija otpornih na lopinavir, pogledati Sažetak opisa svojstava lijeka za Aptivus.
− If you notice you miss a dose within 12 hours of your normal dosing time, take your missed dose as soon as possible, and then continue with your normal dose at the regular time as prescribed by your doctor. 
Ako unutar 12 sati od vremena kada ste trebali uzeti lijek primijetite da ste propustili uzeti jednu dozu, što prije uzmite propuštenu dozu, a potom nastavite uzimati lijek prema uobičajenom rasporedu kako Vam je propisao Vaš liječnik.
Trazodone: AUC: ↑ 2.4-fold 
Trazodon: AUC: ↑ 2,4 puta
They are available in blister multipacks of 60 or 60x1 (2 cartons of 30 or 30x1) film-coated tablets and in plastic bottles (containing a desiccant, which should not be eaten) of 60 film-coated tablets. 
Dostupne su blister višestruka pakiranja sa 60 ili 60 x 1 (2 kutije s 30 ili 30 x 1) filmom obloženih tableta i u plastičnim bocama (koje sadrže sredstvo za sušenje koji se ne smije jesti) sa 60 filmom obloženih tableta.
Erectile dysfunction, menstrual disordersamenorrhoea, menorrhagia 
Erektilna disfunkcija, poremećaji menstrualnog ciklusa - amenoreja, menoragija
Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs) Stavudine, Lamivudine 
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze (NRTI; engl. nucleoside/nucleotide reverse transcriptase inhibitor)
Paediatric dosing guidelines without concomitant efavirenz or nevirapine* Weight (kg) 
Smjernice za pedijatrijsko doziranje bez istodobne primjene efavirenza i nevirapina*
Safety, efficacy and pharmacokinetic profiles of the two dose regimens were assessed after 3 weeks of therapy in each patient. 
U svakog su bolesnika nakon 3 tjedna liječenja procijenjeni sigurnost, djelotvornost i farmakokinetički profil sheme od dvije doze dnevno.
Therefore, lopinavir/ritonavir tablets may be taken with or without food. 
Iz toga proizlazi da se tablete lopinavira/ritonavira mogu uzimati s ili bez hrane.
− Lopinavir/ritonavir should always be taken every day to help control your HIV infection, no matter how much better you feel. 
Bez obzira koliko se bolje počnete osjećati, lopinavir/ritonavir morate uzimati svaki dan kako bi pomogao u kontroli Vaše HIV infekcije.
When co-administered with carbamazepine or phenobarbital, an increase of Lopinavir/Ritonavir Mylan dosage may be envisaged. 
Pri istodobnoj primjeni s karbamazepinom ili fenobarbitalom treba razmotriti povećanje doze lijeka Lopinavir/Ritonavir Mylan.
Ketoconazole, Itraconazole: Serum concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir. 
Ketokonazol, itrakonazol: Serumske koncentracije mogu biti povećane zbog inhibicijskog učinka lopinavira/ritonavira na CYP3A.
They are available in blister multipacks of 120, 120x1 (4 cartons of 30 or 30x1) or 360 (12 cartons of 30) film-coated tablets and in plastic bottles (containing a desiccant, which should not be eaten) of 120 filmcoated tablets and a multipack containing 360 (3 bottles of 120) film-coated tablets. 
Dostupne su blister višestruka pakiranja sa 120, 120 x 1 (4 kutije s 30 ili 30 x 1) ili 360 (12 kutija sa 30) filmom obloženih tableta i u plastičnim bocama (koje sadrže sredstvo za sušenje koji se ne smije jesti) sa 120 filmom obloženih tableta i višestruka pakiranja koje sadrži 360 (3 boce sa 120) filmom obloženih tableta.
Modest decreases in amprenavir activity were noted with a median increase of IC50 from 3.7- to 8-fold in the baseline and rebound isolates, respectively. 
Umjerenja sniženja aktivnosti amprenavira su primjećena s medijanom porasta IC50 od 3,7 puta u sojeva izoliranih na početku do 8 puta u izoliranih sojeva nakon ponovnog porasta broja virusa.
HIV RNA < 50 copies/ml 
HIV RNA < 50 kopija/ml
AUC:↑ 5.7-fold 
AUC: ↑ 5,7 puta
Increased risk of side-effects (respiratory depression, sedation) due to higher plasma concentrations because of CYP3A4 inhibition by lopinavir/ritonavir. 
Povećan rizik od nuspojava (depresija disanja, sedacija) usljed viših koncentracija u plazmi, nastalih zbog inhibicije CYP3A4 lopinavirom/ritonavirom.
Posology 
PISMU
Increased plasma concentrations of quetiapine which may lead to coma. 
Povišena koncentracija kvetiapina u plazmi što može dovesti do kome.
Antiviral activity of lopinavir/ritonavir in patients failing protease inhibitor therapy The clinical relevance of reduced in vitro susceptibility to lopinavir has been examined by assessing the virologic response to lopinavir/ritonavir therapy, with respect to baseline viral genotype and phenotype, in 56 patients previous failing therapy with multiple protease inhibitors. 
Klinički značaj smanjene osjetljivosti na lopinavir in vitro određen je procjenom virološkog odgovora na terapiju lopinavirom/ritonavirom u odnosu na početni virusni genotip i fenotip u 56 bolesnika koji prethodno nisu reagirali na terapiju s više inhibitora proteaze.
Sildenafil used to treat erectile dysfunction may be taken under doctor's supervision (see Other medicines and Lopinavir/ritonavir Mylan section); 
Sildenafil koji se koristi za liječenje erektilne disfunkcije može se koristiti samo pod liječničkim nadzorom (pogledajte dio Drugi lijekovi i Lopinavir/Ritonavir Mylan); pripravke koji sadrže gospinu travu (Hypericum perforatum).
How to take Lopinavir/Ritonavir Mylan 
Kako uzimati Lopinavir/Ritonavir Mylan
Concomitant administration of Lopinavir/Ritonavir Mylan and alfuzosin is contra-indicated (see section 4.3) as alfuzosin-related toxicity, including hypotension, may be increased. 
Istodobna primjena lijeka Lopinavir/Ritonavir Mylan i alfuzosina je kontraindicirana (vidjeti dio 4.3) jer može doći do povećanja toksičnosti povezane s alfuzosinom, uključujući hipotenziju.
Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years. 
Lopinavir/ritonavir je indiciran za liječenje odraslih, adolescenata i djece starije od 2 godine inficiranih virusom humane imunodeficijencije (HIV-1) u kombinaciji s ostalim antiretrovirusnim lijekovima.
Study M98-863 was a randomised, double-blind trial of 653 antiretroviral treatment naïve patients investigating lopinavir/ritonavir (400/100 mg twice daily) compared to nelfinavir (750 mg three times daily) plus stavudine and lamivudine. 
Bolesnici bez ranije terapije antiretrovirusnim lijekovima Studija M98-863 bila je randomizirano, dvostrukoslijepo ispitivanje lopinavira/ritonavira (400/100 mg dvaput na dan) u usporedbi s nelfinavirom (750 mg triput na dan) plus stavudin i lamivudin u 653 bolesnika bez prethodne antiretrovirusne terapije.
Trazodone single dose (Ritonavir, 200 mg BID) 
Antidepresivi i anksiolitici Trazodon jednokratna doza (Ritonavir, 200 mg BID)
AUC: ↑ 6.10-fold Cmax: ↑ 4.76-fold Ctrough: ↑ 12.33-fold 
AUC: ↑ 6,10 puta Cmax: ↑ 4,76 puta Ctrough: ↑ 12,33 puta
The use of rivaroxaban is not recommended in patients receiving concomitant treatment with Lopinavir/Ritonavir Mylan (see section 4.4). 
Ne preporučuje se primjena rivaroksabana kod bolesnika koji se istodobno liječe lijekom Lopinavir/Ritonavir Mylan (vidjeti dio 4.4).
Patients were randomised in a 1:1 ratio to receive either lopinavir/ritonavir 800/200 mg once daily (n = 333) or lopinavir/ritonavir 400/100 mg twice daily (n = 331). 
Bolesnici su bili podijeljeni u grupe u omjeru 1:1 na taj način da su jedni primali 800/200 mg lopinavira/ritonavira jednom dnevno (n = 333), a drugi 400/100 mg lopinavira/ritonavira dva puta dnevno (n = 331).
Lopinavir/Ritonavir Mylan contains sodium 
Lopinavir/Ritonavir Mylan sadrži natrij
(inhibition of CYP3A/efflux transporters) 
(inhibicija CYP3/prijenosnika efluksa)
A more pronounced effect on bedaquiline plasma exposures may be observed during prolonged co-administration with lopinavir/ritonavir. 
Mogući je izraženiji učinak na izloženost bedakilinu u plazmi tijekom produljene istodobne primjene s lopinavirom/ritonavirom.
Concomitant administration of Lopinavir/Ritonavir Mylan and ergot alkaloids are contraindicated as it may lead to acute ergot toxicity, including vasospasm and ischaemia (see section 
Istodobna primjena lijeka Lopinavir/Ritonavir Mylan i ergot alkaloida kontraindicirana je jer može dovesti do akutne ergotne toksičnosti, uključujući vazospazam i ishemiju (vidjeti dio 4.3).
AUC: ↑ 2.71-fold Cmax: ↑ 1.87-fold C24: ↑ 3.58-fold 
AUC: ↑ 2,71 put Cmax: ↑ 1,87 puta C24: ↑ 3,58 puta